Last reviewed · How we verify
Individualized approach
At a glance
| Generic name | Individualized approach |
|---|---|
| Also known as | 4 L polyethylene glycol or sodium picosulphate / magnesium citrate |
| Sponsor | Clinical Hospital Colentina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Manipulating Exercise Intensity and Affective Responses for Cardiac Rehabilitation Program Acute Coronary Syndrome Patients (NA)
- Dyad Plus Effectiveness/Feasibility (NA)
- The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
- Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis (NA)
- Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
- Protocol for a Randomized Controlled Trial Comparing the Effectiveness of Mechanical Diagnosis and Therapy Versus Generalized Exercise for Reducing Pain in Surgeons With Chronic Spinal Pain (NA)
- Risk-Based Geriatric Assessment-Driven Management in Older Patients Starting Chemotherapy (NA)
- Transition to Adulthood Through Coaching and Empowerment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Individualized approach CI brief — competitive landscape report
- Individualized approach updates RSS · CI watch RSS
- Clinical Hospital Colentina portfolio CI